ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1843

Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Abstract Number: 0974

Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Abstract Number: 1824

Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
Abstract Number: 0050

TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Abstract Number: 0057

TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
Abstract Number: 1231

TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Abstract Number: 2039

To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists
Abstract Number: 1663

Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
Abstract Number: 0739

Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Abstract Number: 0426

Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.
Abstract Number: 2676

Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab
Abstract Number: 2451

Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Abstract Number: LB02

Tofacitinib Plus Glucocorticoids Can Effectively Reduce Relapse Rate in IgG4-Related Disease: A Randomized,Open-label controlled Trial
Abstract Number: 1541

Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Abstract Number: 1098

Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].